Quantoom Biosciences

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  },
  "legal_form_change": {
    "new": "Soci\u00E9t\u00E9 anonyme",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 11556914.0,
      "delta_eur": 10691300.0,
      "before_eur": 865614.0,
      "subscribers": [
        {
          "kbo": "0744.643.858",
          "rrn": null,
          "kind": "org",
          "name": "Quantoom Biosciences",
          "share_class": null,
          "liberation_pct": null,
          "contribution_kind": "natura",
          "n_shares_subscribed": 10691300,
          "contribution_amount_eur": 10691300.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 10691300,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "natura",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_decrease",
      "after_eur": 61500.0,
      "delta_eur": -11495414.0,
      "before_eur": 11556914.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": "loss_absorption",
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Dimitri CLEENEWERCK de CRAYENCOUR",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2025-01-28",
    "filing_date": "2025-01-24",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2024-12-30",
    "unanimous": true,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": {
    "waived": false,
    "firm_kbo": null,
    "firm_name": "Deloitte R\u00E9viseurs d\u2019Entreprises SRL",
    "ibr_number": null,
    "mission_type": "apport_nature",
    "individual_name": "Julie Delforge"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "exp\u00E9dition conforme de l\u0027acte",
    "procuration",
    "statuts coordonn\u00E9s",
    "rapport du conseil d\u0027administration",
    "rapport du commissaire"
  ],
  "shareholders_after": [
    {
      "kbo": "0744.643.858",
      "pct": null,
      "kind": "org",
      "name": "Quantoom Biosciences",
      "role": "aandeelhouder",
      "n_shares": 45942431,
      "share_class": null
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "org",
      "name": "UNIVERCELLS",
      "role": "aandeelhouder",
      "n_shares": 10691300,
      "share_class": null
    }
  ],
  "share_classes_after": []
}

{
  "notary": {
    "name": "Dimitri CLEENEWERCK de CRAYENCOUR",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2025-01-28",
    "filing_date": "2025-01-24",
    "act_kind_objet": "STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), CAPITAL, ACTIONS"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2024-12-30",
    "unanimous": true
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "targeted_amendment"
    ],
    "scope": "full_restatement",
    "trigger": "wvv_adaptation",
    "language_after": null,
    "language_before": null
  },
  "bedrijfsrevisor": {
    "firm_kbo": null,
    "firm_name": "Deloitte R\u00E9viseurs d\u2019Entreprises SRL",
    "ibr_number": "25307366",
    "individual_name": "Julie Delforge"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full_after": "Quantoom Biosciences",
    "legal_form_after": "Soci\u00E9t\u00E9 anonyme",
    "name_full_before": "Quantoom Biosciences",
    "current_zetel_raw": "rue de la Maitrise 11 1400 Nivelles",
    "legal_form_before": "Soci\u00E9t\u00E9 anonyme"
  },
  "special_mandates": [
    {
      "holder_kbo": null,
      "holder_name": "UNIVERCELLS",
      "scope_categories": [
        "kbo"
      ],
      "with_substitution": false
    }
  ],
  "articles_modified": [
    {
      "summary": "Le capital est fix\u00E9 \u00E0 61.500,00 \u20AC, repr\u00E9sent\u00E9 par 45.942.431 actions sans d\u00E9signation de valeur nominale.",
      "new_text": "ARTICLE 5 - CAPITAL\nLe capital est fix\u00E9 \u00E0 la somme de soixante et un mille cinq cents euros (61.500,00 \u20AC), repr\u00E9sent\u00E9 par quarante-cinq millions neuf cent quarante-deux mille quatre cent trente et un (45.942.431) actions, sans d\u00E9signation de valeur nominale, repr\u00E9sentant chacune un/ quarante-cinq millions neuf cent quarante-deux mille quatre cent trente et uni\u00E8me (1/45.942.431\u00E8me) du capital.",
      "change_kind": "amended",
      "article_title": "CAPITAL",
      "article_number": "5"
    }
  ],
  "governance_change": null,
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Dimitri CLEENEWERCK de CRAYENCOUR",
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "exp\u00E9dition conforme de l\u0027acte",
    "procuration",
    "statuts coordonn\u00E9s",
    "rapport du conseil d\u0027administration",
    "rapport du commissaire"
  ],
  "shareholder_rights": null,
  "voorwerp_change_summary": null,
  "capital_structure_change": {
    "operations": [
      "capital_increase_cash",
      "share_class_creation"
    ],
    "split_ratio": null,
    "shares_after": 45942431,
    "shares_before": 865614,
    "capital_after_eur": 11556914.0,
    "capital_before_eur": 865614.0,
    "share_classes_after": [
      {
        "count": 45942431,
        "label": "actions sans d\u00E9signation de valeur nominale",
        "rights_summary": "offrant les m\u00EAmes droits et avantages, participant aux b\u00E9n\u00E9fices prorata temporis",
        "voting_per_share": null
      }
    ]
  },
  "coordinated_text_lineage": null
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 11556914,
      "delta_eur": 10691300,
      "before_eur": 865614,
      "contribution_type": "natura"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Indekeu - de Crayencour",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-11-21",
    "filing_date": "2024-11-06",
    "act_kind_objet": "D\u00E9p\u00F4t d\u0027un projet commun d\u0027op\u00E9ration assimil\u00E9e \u00E0 une scission partielle"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2024-12-20",
    "unanimous": true
  },
  "conversion": null,
  "detected_kind": "demerger_partial",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0744.643.858",
        "name": "Quantoom Biosciences",
        "role": "demerged",
        "address": "Rue de la Maitrise 11, 1400 Nivelles",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 anonyme",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0502.742.288",
        "name": "UNIVERCELLS",
        "role": "recipient",
        "address": "Zoning de Jumet, avenue Centrale 52, 6040 Charleroi",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 anonyme",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "12:59",
      "12:8",
      "12:60"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2024-09-30",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "La partie \u00E0 scinder comprend l\u0027activit\u00E9 de recherche et d\u00E9veloppement, incluant les moyens op\u00E9rationnels, le personnel, les contrats commerciaux, le fonds de roulement, les subventions, les immobilisations corporelles et incorporelles (notamment brevets, marques, droits d\u0027auteur), ainsi que les donn\u00E9es et bases de donn\u00E9es li\u00E9es \u00E0 cette activit\u00E9. L\u0027ensemble des \u00E9l\u00E9ments non explicitement r\u00E9partis e",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2024-10-01"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences",
    "legal_form": "Soci\u00E9t\u00E9 anonyme"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "H\u00E9lo\u00EFse Van Houtte",
    "org_rep_person_name": null
  },
  "summary_narrative": "Ce document est un projet d\u0027op\u00E9ration assimil\u00E9e \u00E0 une scission partielle, conform\u00E9ment aux articles 12:59 et 12:8 du Code des Soci\u00E9t\u00E9s et des Associations. La soci\u00E9t\u00E9 Quantoom Biosciences, soci\u00E9t\u00E9 anonyme \u00E0 Nivelles, entend transf\u00E9rer une partie de son patrimoine \u2014 notamment son activit\u00E9 de recherche et d\u00E9veloppement, ses actifs immat\u00E9riels, son personnel et ses contrats \u2014 \u00E0 la soci\u00E9t\u00E9 UNIVERCELLS, \u00E9galement soci\u00E9t\u00E9 anonyme \u00E0 Charleroi. L\u0027op\u00E9ration, qui prend effet juridiquement le 20 d\u00E9cembre 2024, est r\u00E9troactive pour les fins comptables et fiscales \u00E0 partir du 1er octobre 2024. Aucune nouve",
  "co_filed_documents": [
    "R\u00E9solution \u00E9crite unanime des administrateurs du 29 octobre 2024",
    "Rapport du commissaire aux comptes Deloitte R\u00E9viseurs d\u0027Entreprises SRL"
  ],
  "detected_real_type": "demerger_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "stage": "proposal",
  "notary": {
    "name": null,
    "firm_city": null,
    "firm_name": null,
    "office_city": null,
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2024-11-21",
    "filing_date": "2024-11-06",
    "act_kind_objet": "D\u00E9p\u00F4t d\u0027un projet commun d\u0027op\u00E9ration assimil\u00E9e \u00E0 une scission partielle"
  },
  "decision": {
    "body": null,
    "act_date": null,
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "demerger_partial",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0744.643.858",
        "name": "Quantoom Biosciences",
        "role": "demerged",
        "address": "Rue de la Maitrise 11, 1400 Nivelles",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 anonyme",
        "is_new_company": false,
        "jurisdiction_country": null
      },
      {
        "kbo": "0502.742.288",
        "name": "UNIVERCELLS",
        "role": "recipient",
        "address": "Zoning de Jumet, avenue Centrale 52, 6040 Charleroi",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 anonyme",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "12:59 juncto 12:8, 2",
      "12:59",
      "12:60",
      "12:59, \u00A72, 9\u00B0",
      "12:59, \u00A72, 2\u00B0 et 10\u00B0",
      "12:59, \u00A72, 3\u00B0",
      "12:59, \u00A72, 4\u00B0",
      "12 :59, \u00A72, 5\u00B0",
      "12:50, 6\u00B0",
      "12:59, $2, 7\u00B0",
      "12:59, \u00A72, 8\u00B0"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": null,
    "real_estate_included": true,
    "patrimony_description": "La partie \u00E0 scinder est compos\u00E9e de l\u0027activit\u00E9 de recherche et d\u00E9veloppement exerc\u00E9e par la Soci\u00E9t\u00E9 \u00E0 Scinder, incluant les actifs et passifs, les droits et obligations li\u00E9s \u00E0 cette activit\u00E9, tels qu\u0027ils existent \u00E0 la date d\u0027effet juridique de la scission partielle.",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2024-10-01"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences",
    "legal_form": "Soci\u00E9t\u00E9 anonyme"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "H\u00E9lo\u00EFse Van Houtte",
    "org_rep_person_name": null
  },
  "summary_narrative": "Un projet de scission partielle est propos\u00E9 pour transf\u00E9rer l\u0027activit\u00E9 de recherche et d\u00E9veloppement de Quantoom Biosciences (la Soci\u00E9t\u00E9 \u00E0 Scinder) \u00E0 UNIVERCELLS (la Soci\u00E9t\u00E9 B\u00E9n\u00E9ficiaire). L\u0027op\u00E9ration est consid\u00E9r\u00E9e comme silencieuse car la Soci\u00E9t\u00E9 B\u00E9n\u00E9ficiaire d\u00E9tient d\u00E9j\u00E0 l\u0027ensemble des actions de la Soci\u00E9t\u00E9 \u00E0 Scinder, sans \u00E9mission de nouvelles actions. Les op\u00E9rations de la Soci\u00E9t\u00E9 \u00E0 Scinder seront comptabilis\u00E9es pour la Soci\u00E9t\u00E9 B\u00E9n\u00E9ficiaire \u00E0 partir du 1 octobre 2024, et l\u0027op\u00E9ration prendra effet juridiquement le 20 d\u00E9cembre 2024.",
  "co_filed_documents": [],
  "detected_real_type": "demerger_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  },
  "legal_form_change": {
    "new": "",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 5798620.0,
      "delta_eur": 2000000.0,
      "before_eur": 3798620.0,
      "subscribers": [
        {
          "kbo": "0744.643.858",
          "rrn": null,
          "kind": "org",
          "name": "Quantoom Biosciences",
          "share_class": null,
          "liberation_pct": 25.0,
          "contribution_kind": "numeraire",
          "n_shares_subscribed": 2000000,
          "contribution_amount_eur": 2000000.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 2000000,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 1.0
      },
      "decrease_purpose": null,
      "contribution_type": "numeraire",
      "paid_up_delta_eur": 500000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": 1500000.0,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_decrease",
      "after_eur": 865614.0,
      "delta_eur": -4933006.0,
      "before_eur": 5798620.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": "loss_absorption",
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "statutory_reserve_release",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": 865614.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "reserves_incorporation",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
    }
  ],
  "notary": {
    "name": "Dimitri CLEENEWERCK de CRAYENCOUR INDEKEU",
    "firm_city": null,
    "firm_name": "DE CRAYENCOUR",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-02-26",
    "filing_date": "2024-02-22",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2023-12-22",
    "unanimous": true,
    "under_authorized_capital": true,
    "underlying_resolution_date": "2023-12-18"
  },
  "bedrijfsrevisor": {
    "waived": true,
    "firm_kbo": null,
    "firm_name": null,
    "ibr_number": null,
    "mission_type": null,
    "individual_name": null
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "exp\u00E9dition conforme de l\u0027acte",
    "procurations",
    "statuts coordonn\u00E9s",
    "PV du 18 d\u00E9cembre 2023"
  ],
  "shareholders_after": [
    {
      "kbo": "0744.643.858",
      "pct": null,
      "kind": "org",
      "name": "Quantoom Biosciences",
      "role": "aandeelhouder",
      "n_shares": 35251131,
      "share_class": null
    }
  ],
  "share_classes_after": []
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 5798620.0,
      "delta_eur": 2000000.0,
      "before_eur": 3798620.0,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Aziz Kabeer",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Pierre Morgon",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Jean Prieels",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Alerion BV",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Viva Finance SRL",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "auditor",
      "person": {
        "rrn": null,
        "name": "Deloitte R\u00E9viseur d\u0027Entreprises",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "QUANTOOM BIOSCIENCES"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 12386710,
      "delta_eur": 6000000,
      "before_eur": 6386710,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  },
  "legal_form_change": {
    "new": "",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 12386710.0,
      "delta_eur": 6000000.0,
      "before_eur": 6386710.0,
      "subscribers": [
        {
          "kbo": "0744.643.858",
          "rrn": null,
          "kind": "org",
          "name": "Quantoom Biosciences",
          "share_class": null,
          "liberation_pct": 100.0,
          "contribution_kind": "numeraire",
          "n_shares_subscribed": 6000000,
          "contribution_amount_eur": 6000000.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 6000000,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 1.0
      },
      "decrease_purpose": null,
      "contribution_type": "numeraire",
      "paid_up_delta_eur": 6000000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_decrease",
      "after_eur": 3798620.0,
      "delta_eur": -8588090.0,
      "before_eur": 12386710.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": "loss_absorption",
      "contribution_type": "reserves_incorporation",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
    }
  ],
  "notary": {
    "name": "Dimitri CLEENEWERCK de CRAYENCOUR",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2023-09-12",
    "filing_date": "2023-09-08",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2023-08-25",
    "unanimous": true,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": {
    "waived": true,
    "firm_kbo": null,
    "firm_name": null,
    "ibr_number": null,
    "mission_type": null,
    "individual_name": null
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "exp\u00E9dition conforme de l\u0027acte",
    "procurations",
    "statuts coordonn\u00E9s"
  ],
  "shareholders_after": [
    {
      "kbo": "0744.643.858",
      "pct": 100.0,
      "kind": "org",
      "name": "Quantoom Biosciences",
      "role": "aandeelhouder",
      "n_shares": 33251131,
      "share_class": null
    }
  ],
  "share_classes_after": []
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 17480481.0,
      "delta_eur": 13000000.0,
      "before_eur": 4480481.0,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 17480481.0,
      "delta_eur": 13000000.0,
      "before_eur": 4480481.0,
      "subscribers": [
        {
          "kbo": "0744.643.858",
          "rrn": null,
          "kind": "org",
          "name": "Quantoom Biosciences",
          "share_class": null,
          "liberation_pct": 100.0,
          "contribution_kind": "numeraire",
          "n_shares_subscribed": 13000000,
          "contribution_amount_eur": 13000000.0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 13000000,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 1.0
      },
      "decrease_purpose": null,
      "contribution_type": "numeraire",
      "paid_up_delta_eur": 13000000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_decrease",
      "after_eur": 6386710.0,
      "delta_eur": -11093771.0,
      "before_eur": 17480481.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": "loss_absorption",
      "contribution_type": "apurement_pertes",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "statutory_reserve_release",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "kapitalisering_reserves",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Dimitri CLEENEWERCK de CRAYENCOUR",
    "firm_city": null,
    "firm_name": "G\u00E9rard INDEKEU - Dimitri CLEENEWERCK de CRAYENCOUR",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2022-11-24",
    "filing_date": "2022-11-22",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "assembl\u00E9e_generale_extraordinaire",
    "act_date": "2022-11-10",
    "unanimous": true,
    "under_authorized_capital": false,
    "underlying_resolution_date": "2022-11-10"
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Dimitri CLEENEWERCK de CRAYENCOUR",
    "org_rep_person_name": null,
    "person_role_at_subject": "Notaire associ\u00E9"
  },
  "co_filed_documents": [
    "exp\u00E9dition conforme de l\u0027acte",
    "procuration",
    "statuts coordonn\u00E9s"
  ],
  "shareholders_after": [
    {
      "kbo": "0744.643.858",
      "pct": null,
      "kind": "org",
      "name": "Quantoom Biosciences",
      "role": "aandeelhouder",
      "n_shares": 27251131,
      "share_class": null
    }
  ],
  "share_classes_after": []
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 11160394.0,
      "delta_eur": 7000000.0,
      "before_eur": 4160394.0,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Quantoom Biosciences"
  },
  "legal_form_change": {
    "new": "",
    "old": "Soci\u00E9t\u00E9 Anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "ANTROBUS",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "QUANTOOM BIOSCIENCES"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "Quantoom Biosciences",
    "old": "UNIVERCELLS VACCINES",
    "changed": true
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "UNIVERCELLS VACCINES"
  },
  "legal_form_change": {
    "new": "Soci\u00E9t\u00E9 anonyme",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "board member",
      "person": {
        "rrn": null,
        "name": "Jean-Paul Prieels",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "UNIVERCELLS VACCINES"
  }
}

{
  "events": [
    {
      "kind": "capital_decrease",
      "after_eur": 4160394,
      "delta_eur": -3090737,
      "before_eur": 7251131,
      "contribution_type": null
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "UNIVERCELLS VACCINES"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "UNIVERCELLS VACCINES"
  },
  "legal_form_change": {
    "new": "",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Kabeer Aziz",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Pierre Morgon",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "administrateur d\u00E9l\u00E9gu\u00E9",
      "person": {
        "rrn": null,
        "name": "Hugues Bultot",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur d\u00E9l\u00E9gu\u00E9",
      "person": {
        "rrn": null,
        "name": "Jos\u00E9 Castillo",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "Univercells Vaccines"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 7251131,
      "delta_eur": 7189631,
      "before_eur": 61500,
      "contribution_type": "natura"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "UNIVERCELLS VACCINES"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": true
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "UNIVERCELLS VACCINES"
  },
  "legal_form_change": {
    "new": "Soci\u00E9t\u00E9 Anonyme",
    "old": "Soci\u00E9t\u00E9 Anonyme",
    "changed": false
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Sixtine Borres",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Nivelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2020-03-24",
    "filing_date": "2020-03-12",
    "act_kind_objet": "DEPOT D\u0027UN PROJET COMMUN D\u0027APPORT D\u0027UNE BRANCHE D\u0027ACTIVITE"
  },
  "decision": {
    "body": "raad_van_bestuur",
    "act_date": "2020-03-12",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "branch_contribution",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0502.742.288",
        "name": "UNIVERCELLS",
        "role": "contributor",
        "address": "6041 Charleroi, Rue Auguste Piccard 48",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0744.643.858",
        "name": "UNIVERCELLS VACCINES",
        "role": "recipient",
        "address": "1400 Nivelles, Rue de la Ma\u00EEtrise 11",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "12:93"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "La branche d\u0027activit\u00E9 \u0027Vaccins\u0027 est transf\u00E9r\u00E9e de la soci\u00E9t\u00E9 UNIVERCELLS \u00E0 la soci\u00E9t\u00E9 UNIVERCELLS VACCINES. Le transfert concerne l\u0027ensemble des actifs, droits et obligations li\u00E9s \u00E0 cette activit\u00E9.",
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "name_full": "UNIVERCELLS VACCINES",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Sixtine Borres",
    "org_rep_person_name": null
  },
  "summary_narrative": "Le conseil d\u0027administration de la soci\u00E9t\u00E9 anonyme UNIVERCELLS, dont le si\u00E8ge social est \u00E0 Charleroi, a d\u00E9cid\u00E9, le 12 mars 2020, de transf\u00E9rer sa branche d\u0027activit\u00E9 \u0027Vaccins\u0027 \u00E0 la soci\u00E9t\u00E9 anonyme UNIVERCELLS VACCINES, dont le si\u00E8ge social est \u00E0 Nivelles. Ce projet d\u0027apport de branche d\u0027activit\u00E9 est soumis \u00E0 d\u00E9p\u00F4t et publication conform\u00E9ment \u00E0 l\u0027article 12:93 du Code des soci\u00E9t\u00E9s et des associations.",
  "co_filed_documents": [],
  "detected_real_type": "branch_contribution",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "notary": {
    "name": "G\u00E9rard INDEKEU",
    "firm_city": null,
    "firm_name": "G\u00E9rard INDEKEU - Dimitri CLEENEWERCK de CRAYENCOUR",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2020-03-04",
    "filing_date": "2020-03-02",
    "act_kind_objet": "Objet de l\u0027acte:",
    "is_private_deed": false
  },
  "decision": {
    "body": "notarieel_alleen",
    "act_date": "2020-02-28",
    "unanimous": true
  },
  "founders": [
    {
      "org": {
        "kbo": "0502.742.288",
        "name": "UNIVERCELLS",
        "address": "6041 Charleroi, Rue Auguste Piccard 48",
        "country": "BE",
        "legal_form": "SA",
        "foreign_register_name": null,
        "foreign_register_number": null
      },
      "kind": "rechtspersoon",
      "person": null,
      "share_class": null,
      "partner_role": "null",
      "contribution_type": "geld",
      "amount_paid_in_eur": 61500.0,
      "is_subscriber_only": false,
      "n_shares_subscribed": 61500,
      "amount_subscribed_eur": 61500.0,
      "is_anonymous_silent_partner": false
    }
  ],
  "voorwerp": {
    "full_text": "La soci\u00E9t\u00E9 a pour objet, en Belgique et \u00E0 l\u0027\u00E9tranger, soit directement, soit comme interm\u00E9diaire, tant pour son compte propre que pour le compte de tiers, sauf disposition contraire, ce qui est pr\u00E9vu ci-apr\u00E8s : Favoriser le d\u00E9veloppement de la recherche m\u00E9dicale et biom\u00E9dicale au sens large en vue d\u2019\u00E9laborer et concevoir des produits de toute nature incluant des m\u00E9dicaments ou des techniques m\u00E9dicales, en vue de favoriser tous services, savoir faires ou syst\u00E8mes techniques, sociologiques, philosophiques, psychologiques pouvant contribuer, de mani\u00E8re innovante, \u00E0 la sant\u00E9 et/ou au bien-\u00EAtre de l\u2019homme dans le respect de l\u2019environnement. L\u2019utilisation, la recherche, le d\u00E9veloppement en ce compris l\u2019organisation de tests cliniques, l\u2019exploitation, la transformation, le conditionnement, la fabrication, la promotion, l\u2019achat et la commercialisation sous toutes ses formes de tous produits chimiques ou biologiques, de tous s\u00E9rums, vaccins, toxines, biosimilaires et de tous produits, sous-produits ou d\u00E9riv\u00E9s d\u2019origine animale, v\u00E9g\u00E9tale, microbienne, pouvant servir sous une forme quelconque au diagnostic, \u00E0 la prophylaxie et \u00E0 la th\u00E9rapeutique des maladies humaines ou animales. La recherche et le d\u00E9veloppement, la promotion, l\u2019achat et la vente de tous produits pharmaceutiques, th\u00E9rapeutiques, cosm\u00E9tiques, di\u00E9t\u00E9tiques, \u00E0 usage humain, v\u00E9g\u00E9tal, animal, biologiques, produits chimiques, de tous mat\u00E9riels et instruments m\u00E9dicaux et chirurgicaux, et de mani\u00E8re g\u00E9n\u00E9rale, tous op\u00E9rations industrielles, commerciales, financi\u00E8res ou civiles se rapportant directement ou indirectement aux activit\u00E9s dans le domaine de l\u2019industrie biopharmaceutique. La soci\u00E9t\u00E9 peut r\u00E9aliser tous travaux et tout acte juridique qui sont de nature \u00E0 stimuler directement la r\u00E9alisation de son objet et notamment tout acte mobilier ou immobilier par rapport aux locaux m\u00E9dicaux, l\u2019achat et la vente du mat\u00E9riel m\u00E9dical et non-m\u00E9dical, le recrutement du personnel administratif ou soignant, en service dans la soci\u00E9t\u00E9. Elle ne peut cependant pas faire des actes qui sont contradictoires aux r\u00E8gles de la d\u00E9ontologie m\u00E9dicale. Elle peut constituer, d\u00E9velopper et g\u00E9rer un patrimoine mobilier et faire toutes op\u00E9rations mobili\u00E8res quelconques y compris celles se rapportant \u00E0 tous droits mobiliers comme l\u0027acquisition par voie d\u0027inscription ou de cession et la gestion d\u0027actions, de parts sociales, d\u0027obligations convertibles ou non, de pr\u00EAts de consommation, de pr\u00EAts ordinaires, de bons de caisse ou autres valeurs mobili\u00E8res, de quelque forme que ce soit, tant de personnes morales que d\u0027entreprises, belges ou \u00E9trang\u00E8res, existantes ou encore \u00E0 constituer. La soci\u00E9t\u00E9 pourra exercer tout mandat g\u00E9n\u00E9ralement quelconque ainsi que toute fonction autoris\u00E9e dans toute personne morale belge ou \u00E9trang\u00E8re en ce compris la fonction d\u2019administrateur, de d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re, de g\u00E9rant et de liquidateur. Ce mandat pourra \u00EAtre r\u00E9mun\u00E9r\u00E9 ou gratuit. La soci\u00E9t\u00E9 peut, par voie d\u0027apport en esp\u00E8ces ou en nature, de fusion, de souscription, de participation, d\u0027intervention financi\u00E8re ou autrement, prendre des participations dans d\u0027autres soci\u00E9t\u00E9s ou entreprises existantes ou \u00E0 cr\u00E9er, que ce soit en Belgique ou \u00E0 l\u0027\u00E9tranger, dont l\u0027objet serait semblable ou analogue au sien ou de nature \u00E0 favoriser son objet. Elle peut \u00E9galement consentir tous pr\u00EAts ou garantir tous pr\u00EAts consentis par des tiers, \u00E9tant entendu que la soci\u00E9t\u00E9 n\u0027effectuera aucune activit\u00E9 dont l\u2019exercice serait soumis \u00E0 des dispositions l\u00E9gales ou r\u00E9glementaires applicables aux \u00E9tablissements de cr\u00E9dits et/ou financiers. Elle peut faire toutes op\u00E9rations se rapportant directement ou indirectement au management en g\u00E9n\u00E9ral, et plus pr\u00E9cis\u00E9ment, sans que cette \u00E9num\u00E9ration ne soit limitative : la cr\u00E9ation de soci\u00E9t\u00E9s holding ou d\u0027exploitation, toutes activit\u00E9s d\u0027\u00E9tudes et de conseils, toutes prestations de services, tous travaux d\u0027administration, de gestion, tant aupr\u00E8s des entreprises que des particuliers. Elle peut octroyer des conseils et assister en toutes mati\u00E8res \u00E0 des entreprises et \u00E0 l\u2019administration et la gestion d\u2019entreprises. Elle peut faire toutes op\u00E9rations commerciales, industrielles et financi\u00E8res, immobili\u00E8res et mobili\u00E8res, se rapportant directement ou indirectement \u00E0 son objet ou susceptibles de favoriser son d\u00E9veloppement, \u00E0 l\u0027exception des op\u00E9rations sur valeurs mobili\u00E8res et immobili\u00E8res r\u00E9serv\u00E9es par la loi aux banques et aux soci\u00E9t\u00E9s de bourse. Elle peut constituer, d\u00E9velopper, promouvoir et g\u00E9rer un patrimoine immobilier, et r\u00E9aliser toute op\u00E9ration immobili\u00E8re et fonci\u00E8re quelconque, y compris celles se rapportant \u00E0 tous droits r\u00E9els immobiliers comme, entre autres, l\u0027emphyt\u00E9ose, la superficie ou encore le leasing immobilier, le tout dans son acceptation la plus large et notamment : l\u0027acquisition, l\u0027ali\u00E9nation, l\u0027acte de grever, l\u0027\u00E9change, la r\u00E9novation, la transformation, l\u0027am\u00E9nagement, l\u0027entretien, le lotissement, la prospection, l\u0027exploitation, la pr\u00E9paration pour construire, la locatio",
    "is_lucrative": true,
    "short_summary": "D\u00E9veloppement de la recherche m\u00E9dicale et biom\u00E9dicale, notamment dans les domaines des m\u00E9dicaments, vaccins, produits biologiques, mat\u00E9riel m\u00E9dical et activit\u00E9s connexes, tant en Belgique qu\u2019\u00E0 l\u2019\u00E9tranger."
  },
  "governance": {
    "organ_kind": "raad_van_bestuur",
    "n_directors_max": 0,
    "n_directors_min": 2,
    "representation_clause": "deux administrateurs agissant conjointement ou un administrateur d\u00E9l\u00E9gu\u00E9 agissant seul",
    "co_signature_threshold_eur": null
  },
  "fiscal_year": {
    "end_mm_dd": "12-31",
    "start_mm_dd": "01-01",
    "first_exercise_end_date": "2020-12-31",
    "is_prolonged_first_exercise": false
  },
  "agm_schedule": {
    "time": "19:00",
    "month": 6,
    "rule_text": "troisi\u00E8me jeudi du mois de juin"
  },
  "founding_event": {
    "n_shares_total": 61500,
    "n_share_classes": 1,
    "bank_attestation": null,
    "amount_paid_in_eur": 61500.0,
    "incorporation_date": "2020-02-28",
    "amount_subscribed_eur": 61500.0,
    "art_5_8_no_payment_due": false,
    "pre_incorporation_activity_from_date": null
  },
  "subject_company": {
    "kbo": "0744.643.858",
    "email": null,
    "region": "waals_gewest",
    "website": null,
    "name_full": "UNIVERCELLS VACCINES",
    "legal_form": "SA",
    "name_abbreviated": null,
    "zetel_address_raw": "1400 Nivelles, Rue de la Ma\u00EEtrise 11",
    "equity_account_type": "unavailable",
    "_kbo_filled_from_list": true
  },
  "initial_directors": [
    {
      "kind": "natural_person",
      "person": {
        "name": "Hugues BULTOT",
        "address": "1150 Woluwe-Saint-Pierre, Avenue de l\u0027Horizon 24"
      },
      "via_org": null,
      "role_sub": "administrateur",
      "mandate_until": {
        "kind": "until_agm_year",
        "value": 2026
      },
      "rep_person_name": null,
      "additional_roles": [
        "administrateur-d\u00E9l\u00E9gu\u00E9"
      ],
      "bestuursverbod_checked": false,
      "bestuursverbod_check_date": null,
      "rep_prior_publication_ref": null
    },
    {
      "kind": "natural_person",
      "person": {
        "name": "Jos\u00E9 CASTILLO",
        "address": "1000 Bruxelles, Rue de la Buanderie 18 bo\u00EEte b3.1"
      },
      "via_org": null,
      "role_sub": "administrateur",
      "mandate_until": {
        "kind": "until_agm_year",
        "value": 2026
      },
      "rep_person_name": null,
      "additional_roles": [
        "pr\u00E9sident du conseil d\u0027administration"
      ],
      "bestuursverbod_checked": false,
      "bestuursverbod_check_date": null,
      "rep_prior_publication_ref": null
    }
  ],
  "co_filed_documents": [
    "expedition",
    "statuten",
    "volmacht"
  ],
  "post_incorporation_mandates": [
    {
      "kind": "volmacht_kbo",
      "holder_org_kbo": null,
      "holder_org_name": "PwC Legal",
      "with_substitution": true,
      "holder_person_name": null
    }
  ]
}